Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR

Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR

Plasma cell‐free DNA (cfDNA) analysis to track estrogen receptor 1 (ESR1) mutations is highly beneficial for the identification of tumor molecular dynamics and the improvement of personalized treatments for patients with metastatic breast cancer (MBC). Plasma‐cfDNA is, up to now, the most frequent l...

Full description

Saved in:
Bibliographic Details
Main Authors: Stavroula Smilkou, Aliki Ntzifa, Victoria Tserpeli, Ioanna Balgkouranidou, Alkistis Papatheodoridi, Evangelia Razis, Helena Linardou, Christos Papadimitriou, Amanda Psyrri, Flora Zagouri, Stylianos Kakolyris, Evi Lianidou
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Molecular Oncology
Subjects:
breast cancer
circulating tumor cells
circulating tumor DNA
droplet digital PCR
ESR1 mutations
liquid biopsy
Online Access:https://doi.org/10.1002/1878-0261.13787
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items